Predictors of Long‐term Adherence to Evidence‐based Cardiovascular Disease Medications in Outpatients With Stable Atherothrombotic Disease: Findings From the REACH Registry
dc.contributor.author | Rodriguez, Fátima | en_US |
dc.contributor.author | Cannon, Christopher P. | en_US |
dc.contributor.author | Steg, Ph. Gabriel | en_US |
dc.contributor.author | Kumbhani, Dharam J. | en_US |
dc.contributor.author | Goto, Shinya | en_US |
dc.contributor.author | Smith, Sidney C. | en_US |
dc.contributor.author | Eagle, Kim A. | en_US |
dc.contributor.author | Ohman, E. Magnus | en_US |
dc.contributor.author | Umez‐eronini, Amarachi A. | en_US |
dc.contributor.author | Hoffman, Elaine | en_US |
dc.contributor.author | Bhatt, Deepak L. | en_US |
dc.date.accessioned | 2014-01-08T20:34:56Z | |
dc.date.available | 2015-02-03T16:14:40Z | en_US |
dc.date.issued | 2013-12 | en_US |
dc.identifier.citation | Rodriguez, Fátima ; Cannon, Christopher P.; Steg, Ph. Gabriel; Kumbhani, Dharam J.; Goto, Shinya; Smith, Sidney C.; Eagle, Kim A.; Ohman, E. Magnus; Umez‐eronini, Amarachi A. ; Hoffman, Elaine; Bhatt, Deepak L. (2013). "Predictors of Longâ term Adherence to Evidenceâ based Cardiovascular Disease Medications in Outpatients With Stable Atherothrombotic Disease: Findings From the REACH Registry." Clinical Cardiology 36(12): 721-727. | en_US |
dc.identifier.issn | 0160-9289 | en_US |
dc.identifier.issn | 1932-8737 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/102180 | |
dc.description.abstract | Background Despite overall improvements in cardiovascular‐disease therapies and outcomes, medication nonadherence remains an important barrier to effective secondary prevention of atherothrombotic disease. Hypothesis Long‐term medication adherence in outpatients with stable atherothrombotic disease is impacted by demographic and clinical factors. Methods We examined data from the prospective international Reduction of Atherothrombosis for Continued Health ( REACH ) Registry. Analyses were derived from 25 737 patients with established atherothrombotic disease with complete adherence data at enrollment and at year 4. Adherence was defined as patients' self‐report of taking medications based on class I American College of Cardiology/American Heart Association guidelines for secondary prevention as defined, including antiplatelet agents, statins, and antihypertensive medications. Results Among patients with atherothrombotic disease, 12 500 (48.6%) were deemed adherent to guideline‐recommended medications. Adherent patients were younger, white, and had less polyvascular disease. Hispanic and East Asian patients were less likely to be adherent as compared with white patients (odds ratio [ OR ]: 0.72, 95% confidence interval [ CI ]: 0.59‐0.88; and OR : 0.67, 95% CI : 0.53‐0.83, respectively). Patients who had a nonfatal MI or underwent coronary angioplasty/stenting during follow‐up were more likely to be adherent compared with patients without these events ( OR : 1.73, 95% CI : 1.25‐2.38; and OR : 2.15, 95% CI : 1.72‐2.67, respectively). On the other hand, nonfatal stroke during follow‐up was inversely associated with adherence ( OR : 0.77, 95% CI : 0.61‐0.97). Conclusions Using a large international registry of outpatients with atherothrombotic disease, we found that age, region, race/ethnicity, and incident cardiovascular events were predictive of long‐term guideline adherence for secondary prevention, suggesting that certain patient groups may benefit from targeted interventions to improve adherence. | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.title | Predictors of Long‐term Adherence to Evidence‐based Cardiovascular Disease Medications in Outpatients With Stable Atherothrombotic Disease: Findings From the REACH Registry | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialities | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/102180/1/clc22217.pdf | |
dc.identifier.doi | 10.1002/clc.22217 | en_US |
dc.identifier.source | Clinical Cardiology | en_US |
dc.identifier.citedreference | Roth MT, Esserman DA, Ivey JL, et al. Racial disparities in quality of medication use in older adults: findings from a longitudinal study. Am J Geriatr Pharmacother. 2011; 9: 250 – 258. | en_US |
dc.identifier.citedreference | Kumbhani DJ, Fonarow GC, Cannon CP, et al. Predictors of adherence to performance measures in patients with acute myocardial infarction. Am J Med. 2013; 126:74.e1–74.e9. | en_US |
dc.identifier.citedreference | Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006; 295: 180 – 189. | en_US |
dc.identifier.citedreference | Ohman EM, Bhatt DL, Steg PG, et al. The Reduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events—study design. Am Heart J. 2006; 151:786.e1–786.e10. | en_US |
dc.identifier.citedreference | Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4‐year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010; 304: 1350 – 1357. | en_US |
dc.identifier.citedreference | Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006; 113: 2363 – 2372. | en_US |
dc.identifier.citedreference | Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011; 42: 227 – 276. | en_US |
dc.identifier.citedreference | Baker DW, Hayes R, Fortier JP. Interpreter use and satisfaction with interpersonal aspects of care for Spanish‐speaking patients. Med Care. 1998; 36: 1461 – 1470. | en_US |
dc.identifier.citedreference | Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006; 166: 1842 – 1847. | en_US |
dc.identifier.citedreference | Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid‐lowering medications a cross‐national study. JAMA. 1998; 279: 1458 – 1462. | en_US |
dc.identifier.citedreference | Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther. 1998; 20: 764 – 771. | en_US |
dc.identifier.citedreference | Kulik A, Shrank WH, Levin R, et al. Adherence to statin therapy in elderly patients after hospitalization for coronary revascularization. Am J Cardiol. 2011; 107: 1409 – 1414. | en_US |
dc.identifier.citedreference | Mensah GA, Mokdad AH, Ford ES, et al. State of disparities in cardiovascular health in the united states. Circulation. 2005; 111: 1233 – 1241. | en_US |
dc.identifier.citedreference | Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high‐income, middle‐income, and low‐income countries (the PURE study) a prospective epidemiological survey. Lancet. 2011; 378: 1231 – 1243. | en_US |
dc.identifier.citedreference | Shrank WH. Helping our patients to adhere to chronic medications a new arrow for the quiver. J Gen Intern Med. 2011; 26: 1394 – 1395. | en_US |
dc.identifier.citedreference | Bowry AD, Shrank WH, Lee JL, et al. A systematic review of adherence to cardiovascular medications in resource‐limited settings. J Gen Intern Med. 2011; 26: 1479 – 1491. | en_US |
dc.identifier.citedreference | Eagle KA, Kline‐Rogers E, Goodman SG, et al. Adherence to evidence‐based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med. 2004; 117: 73 – 81. | en_US |
dc.identifier.citedreference | Edmondson D, Horowitz CR, Goldfinger JZ, et al. Concerns about medications mediate the association of posttraumatic stress disorder with adherence to medication in stroke survivors. Br J Health Psychol. 2013; doi:10.1111/bjhp.12022. | en_US |
dc.identifier.citedreference | Kronish IM, Edmondson D, Goldfinger JZ, et al. Posttraumatic stress disorder and adherence to medications in survivors of strokes and transient ischemic attacks. Stroke. 2012; 43: 2192 – 2197. | en_US |
dc.identifier.citedreference | Qureshi SU, Long ME, Bradshaw MR, et al. Does PTSD impair cognition beyond the effect of trauma? J Neuropsychiatry Clin Neurosci. 2011; 23: 16 – 28. | en_US |
dc.identifier.citedreference | Lonn E, Bosch J, Teo KK, et al. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation. 2010; 122: 2078 – 2088. | en_US |
dc.identifier.citedreference | Thom S, Field J, Poulter N, et al. Use of a Multidrug Pill in Reducing Cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill‐based strategy in India and Europe. Eur J Prev Cardiol. 2012; doi:10.1177/2047487312463278. | en_US |
dc.identifier.citedreference | Thom S. Use of Multidrug Pill in Reducing Cardiovascular Events (UMPIRE): late‐breaking clinical trials. American Heart Association Scientific Sessions; November 3–7; Los Angeles, CA: doi:10.1161/CIR.0b013e318278c90d. | en_US |
dc.identifier.citedreference | Gehi AK, Ali S, Na B, et al. Self‐reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the Heart and Soul Study. Arch Intern Med. 2007; 167: 1798 – 1803. | en_US |
dc.identifier.citedreference | Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009; 119: 3028 – 3035. | en_US |
dc.identifier.citedreference | Newby LK, LaPointe NM, Chen AY, et al. Long‐term adherence to evidence‐based secondary prevention therapies in coronary artery disease. Circulation. 2006; 113: 203 – 212. | en_US |
dc.identifier.citedreference | Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol. 2006; 47: 2130 – 2139. | en_US |
dc.identifier.citedreference | Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation. 2008; 117: 1028 – 1036. | en_US |
dc.identifier.citedreference | Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005; 353: 487 – 497. | en_US |
dc.identifier.citedreference | Kulkarni SP, Alexander KP, Lytle B, et al. Long‐term adherence with cardiovascular drug regimens. Am Heart J. 2006; 151: 185 – 191. | en_US |
dc.identifier.citedreference | Choudhry NK, Setoguchi S, Levin R, et al. Trends in adherence to secondary prevention medications in elderly post–myocardial infarction patients. Pharmacoepidemiol Drug Saf. 2008; 17: 1189 – 1196. | en_US |
dc.identifier.citedreference | Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008; 155: 772 – 779. | en_US |
dc.identifier.citedreference | Wijeysundera HC, Machado M, Farahati F, et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994–2005. JAMA. 2010; 303: 1841 – 1847. | en_US |
dc.identifier.citedreference | Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980‐2000. N Engl J Med. 2007; 356: 2388 – 2398. | en_US |
dc.identifier.citedreference | Kumbhani DJ, Steg PG, Cannon CP, et al. Adherence to secondary prevention medications and four‐year outcomes in outpatients with atherosclerosis. Am J Med. 2013; 126: 693 – 700. | en_US |
dc.identifier.citedreference | Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011; 124: 2458 – 2473. | en_US |
dc.identifier.citedreference | Kolandaivelu K, Bhatt DL. Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence. Nat Rev Cardiol. 2010; 7: 461 – 467. | en_US |
dc.identifier.citedreference | Maddox TM, Ho PM. Medication adherence and the patient with coronary artery disease: challenges for the practitioner. Curr Opin Cardiol. 2009; 24: 468 – 472. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.